Advertisement
U.S. markets close in 1 hour 6 minutes
  • S&P 500

    5,254.50
    +6.01 (+0.11%)
     
  • Dow 30

    39,791.29
    +31.21 (+0.08%)
     
  • Nasdaq

    16,384.53
    -14.99 (-0.09%)
     
  • Russell 2000

    2,122.66
    +8.31 (+0.39%)
     
  • Crude Oil

    83.12
    +1.77 (+2.18%)
     
  • Gold

    2,239.80
    +27.10 (+1.22%)
     
  • Silver

    24.93
    +0.18 (+0.72%)
     
  • EUR/USD

    1.0790
    -0.0040 (-0.37%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2617
    -0.0021 (-0.16%)
     
  • USD/JPY

    151.3820
    +0.1360 (+0.09%)
     
  • Bitcoin USD

    70,429.12
    +1,639.33 (+2.38%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Meridian Bioscience: Q1 Earnings Insights

 

Shares of Meridian Bioscience (NASDAQ:VIVO) moved higher by 5.5% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share increased 550.00% year over year to $0.65, which beat the estimate of $0.42.

Revenue of $92,917,000 higher by 95.94% year over year, which beat the estimate of $83,890,000.

Guidance

The upcoming fiscal year's EPS expected to be between $1.70 and $1.90.

The upcoming fiscal year's revenue expected to be between $320,000,000 and $350,000,000.

Details Of The Call

Date: Feb 05, 2021

View more earnings on VIVO

Time: 10:00 AM

ET Webcast URL: https://investor.meridianbioscience.com/events/event-details/q1-2021-financial-results-conference-call

Price Action

52-week high: $26.58

Company's 52-week low was at $5.51

Price action over last quarter: Up 38.12%

Company Profile

Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement